Fulzerasib联合西妥昔单抗一线治疗KRASG12C突变NSCLC的1b/2期研究
这项单臂、多中心1b/2期试验在西班牙、意大利和希腊的30个中心入组47例未经系统治疗的KRASG12C突变晚期NSCLC患者,接受口服fulzerasib 600 mg每日两次联合静脉西妥昔单抗500 mg/m2每两周一次。确认的客观缓解率为69%(90% CI 56-80),治疗相关不良事件发生率为87%,3级为15%,无4级或5级事件。结论认为该联合方案在初治患者中显示出令人鼓舞的活性和良好的安全性,计划开展3期研究。
要点
- 初治KRASG12C突变NSCLC中fulzerasib联合西妥昔单抗确认ORR达69%(90% CI 56-80)。
- 治疗相关不良事件发生率87%,3级15%,无4级或5级事件。
- 6%患者因不良事件停药,且仅停用西妥昔单抗。
核心结论
- 在未经系统治疗的KRASG12C突变晚期NSCLC中,fulzerasib联合西妥昔单抗显示出令人鼓舞的抗肿瘤活性和良好的安全性。
研究设计与样本
- 单臂、多中心1b/2期试验,在西班牙、意大利和希腊的30个医疗中心入组患者。
- 47例KRASG12C突变NSCLC患者接受fulzerasib 600 mg口服每日两次联合西妥昔单抗500 mg/m2静脉每两周一次。
- 主要终点为研究者按RECIST 1.1评估的客观缓解率,在全分析集中评估。
主要发现
- 确认的客观缓解率为69%(90% CI 56-80)。
- 治疗相关不良事件发生于47例中的41例(87%),3级为7例(15%)。
- 未观察到4级或5级治疗相关不良事件。
- 3例(6%)患者因治疗相关不良事件停药,且仅停用西妥昔单抗。
关键数值与推荐
- 入组条件为KRASG12C突变NSCLC、既往未接受晚期或转移性疾病的系统抗肿瘤治疗、年龄≥18岁。
- 入组要求至少一个按RECIST 1.1可测量病灶、ECOG体能状态0或1、预期寿命≥3个月。
- 给药方案为fulzerasib 600 mg口服每日两次联合西妥昔单抗500 mg/m2静脉每两周一次。
临床怎么用
- 该联合方案可作为初治KRASG12C突变NSCLC的潜在治疗选择,但需等待3期研究进一步验证。
- 治疗期间需关注治疗相关不良事件,3级事件发生率为15%,多数患者可耐受。
局限性
- 本研究为单臂设计,无对照组,结论需随机对照试验验证。
- 样本量较小,共47例患者接受治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fulzerasib, a KRASG12C inhibitor, has shown clinical activity in previously treated non-small-cell lung cancer (NSCLC). Clinical studies indicate that combining a KRASG12C inhibitor with an anti-EGFR antibody is effective in colorectal cancer; however, its benefit in NSCLC remains to be explored. METHODS: This single-arm, phase 1b/2 trial enrolled patients at 30 medical centres in Spain, Italy, and Greece. Eligible patients had KRASG12C-mutated NSCLC with no previous systemic anti-tumour therapy for advanced or metastatic disease and were aged 18 years and older; had at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1; had an Eastern Cooperative Oncology Group performance status of 0 or 1; and had a life expectancy of 3 months or more. Enrolled patients received 600 mg oral fulzerasib twice daily plus 500 mg/m2 intravenous cetuximab every 2 weeks. The primary endpoint was investigator-assessed objective response rate per RECIST 1.1 assessed in the full response analysis set. The study was registered with ClinicalTrials.gov (NCT05756153) and is complete. FINDINGS: Between April 23, 2023, and April 15, 2024, a total of 60 patients were screened, and 47 patients (78%) received treatment. The median age was 68 years (IQR 59-72); 25 patients (53%) were male and 22 (47%) were female. 45 (95%) patients were current or former smokers. As of Jan 14, 2025, the median follow-up time and treatment duration were 12·8 months (90% CI 11·6-14·6) and 10·1 months (IQR 6·3-13·0) months, respectively. The confirmed objective response rate was 69% (90% CI 56-80). Treatment-related adverse events (TRAEs) occurred in 41 (87%) of the 47 patients (grade 3 in seven [15%]). No grade 4 or 5 TRAEs were observed. TRAEs led to drug discontinuation in three (6%) patients, with only cetuximab being discontinued. INTERPRETATION: In treatment-naive KRASG12C-mutated NSCLC, fulzerasib plus cetuximab showed encouraging activity with a favourable safety profile. The combination is currently being planned for investigation in a phase 3 study. FUNDING: Zhejiang GenFleet Therapeutics.
引用
- Gregorc V, Majem M, Lo Russo G, et al. Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial. Lancet Oncol. 2026. PMID: 41926959. doi:10.1016/S1470-2045(25)00764-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。